A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

NCT00617461 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuralgia, Postherpetic

Interventions

DRUG: GEn 1200mg/day
DRUG: GEn 3600mg/day

Sponsor

XenoPort, Inc.